# AHOD1331

Source: https://onco.cc/trials/ahod1331/  
OnCo record `ahod1331` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AHOD1331 showed that replacing bleomycin with the antibody-drug conjugate brentuximab vedotin in the chemotherapy given to children and teenagers with advanced Hodgkin lymphoma cut relapses by more than half without extra side effects, and it became the new standard for high-risk disease.

## Summary

AHOD1331 was an open-label Children's Oncology Group phase 3 trial at 153 institutions that randomised 600 patients (587 eligible) aged 2 to 21 with previously untreated high-risk classical Hodgkin lymphoma to five 21-day cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide, or to the standard paediatric ABVE-PC regimen. Involved-site radiotherapy was given after cycle five to slow-responding lesions on central PET review and to large mediastinal disease. The primary endpoint was event-free survival.

At a median follow-up of 42.1 months three-year event-free survival was 92.1 percent with brentuximab vedotin against 82.5 percent with standard care (hazard ratio 0.41), with similar toxicity and similar use of radiotherapy (53.4 against 56.8 percent); three-year overall survival was 99.3 and 98.5 percent. Brentuximab vedotin was approved in the United States in November 2022 for paediatric high-risk classical Hodgkin lymphoma on this trial. The corpus's Hodgkin lymphoma page cites AHOD1331 for ABVE-PC with brentuximab and PET-guided radiotherapy omission.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-22
- Also known as: COG AHOD1331
- Tags: soc-trials
- Registry id: NCT02166463
- Phase: 3
- Setting: Newly diagnosed high-risk classical Hodgkin lymphoma (stage IIB with bulk, IIIB, IVA or IVB) in patients aged 2 to 21: five cycles of brentuximab vedotin with doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide against standard ABVE-PC, with PET-guided involved-site radiotherapy for slow-responding lesions
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 600
- Result: Three-year event-free survival 92.1 percent with brentuximab vedotin plus AVEPC against 82.5 percent with ABVE-PC (hazard ratio 0.41, p < 0.001), with no increase in toxicity; approved for children in the United States in November 2022.
- Outcomes: Event-free survival at 3 years: Brentuximab vedotin + doxorubicin, vincristine, etoposide, prednisone, cyclophosphamide 92.1% vs ABVE-PC (standard care) 82.5%, HR 0.41; Overall survival at 3 years: Brentuximab vedotin + AVEPC 99.3% vs ABVE-PC (standard care) 98.5%; Patients given involved-site radiotherapy: Brentuximab vedotin + AVEPC 53.4% vs ABVE-PC (standard care) 56.8%

## Sources

- ClinicalTrials.gov NCT02166463: https://clinicaltrials.gov/study/NCT02166463

## Connected records

- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bleomycin](https://onco.cc/drugs/bleomycin/), [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Prednisone](https://onco.cc/drugs/prednisone/), [Vincristine](https://onco.cc/drugs/vincristine/)
- institutions: [Children's Oncology Group (COG)](https://onco.cc/institutions/childrens-oncology-group/)
- key papers: [AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma](https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/ahod1331.json